Rallybio Corporation — Rendiconto Finanziario (NASDAQ:RLYB) | MetaTrader

Apri il grafico completo

Notizie

Il chief medical officer di Rallybio lascia l’azienda con cambio di leadership

Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript

Rallybio to acquire Candid Therapeutics in $505M deal

Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism - Rallybio (NASDAQ:RLYB)

Lieber, CFO di Rallybio, vende azioni per 3.992 dollari

Lieber, Rallybio CFO, sells $3992 in shares

Rallybio reports positive phase 1 results for subcutaneous C5 inhibitor

Rallybio announces one-for-eight reverse stock split effective Feb 6

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested - TipRanks.com

Rallybio implementerà un raggruppamento azionario 1:8 dal 6 febbraio

Rallybio to implement 1-for-8 reverse stock split effective February 6

Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study